TXG

Over the past six months (April - October 2026), 10x Genomics' stock (TXG) experienced significant volatility and a substantial increase, climbing from approximately $41.44 in July 2026 to a 52-week high of $102.81 by early October 2026, representing a gain of over 90% in three months and over 246% in six months. Key events included the commencement of global shipments for the Atera spatial biology platform, a favorable patent infringement verdict against Parse Biosciences, and multiple analyst rating and price target increases. A new collaboration with Fred Hutchinson Cancer Center was announced, and the company reported strong second-quarter 2026 financial results, beating EPS estimates. However, insider selling totaling $16.9 million over the past 12 months with no purchases, and analyses identifying the stock as significantly overvalued, raised some concerns.